Hutchison China MediTech Limited Культура компании

Mr. Christian Hogg, BSc, MBA, has been the Chief Executive Officer of Hutchison China MediTech Ltd., since 2006. Mr. Hogg serves as the Chief Operating Officer of Healthcare Investments of Hutchison Whampoa (China) Limited. He serves as the Chief Operating Officer of Hutchison China's Healthcare business. He joined Hutchison China in 2000, has led all aspects of the creation, implementation and management of the Hutchison China's strategy, business and listing which includes the creation of the Hutchison China's start-up businesses and the acquisition and operational integration of assets that led to the formation of its China joint ventures. He has extensive experience managing and marketing consumer products brands in North America, Europe and Asia while at Procter & Gamble. From 1989 to 1999, he served at Procter & Gamble in the U.S., China and Europe. From 1995 to 1998, he served in China as Brand Manager of the China Laundry Joint Venture business and then as Marketing Manager for Laundry and Cleaning Products, Greater China. In 1999, he served as Global Marketing Director for the 22 country. He has been an Executive Director of Hutchison China MediTech Ltd. since 2006. He serves as a Director of Hutchison Chinese Medicine Holding Limited, Hutchison BYS (Guangzhou) Holding Limited. Mr. Hogg holds a Bachelor's degree in Civil Engineering from the University of Edinburgh, Scotland and an MBA from the University of Tennessee.

Mr. Chi Keung To also known as Simon BSc, ACGI, MBA serves as the Managing Director at Hutchison Whampoa (China) Ltd. (formerly Hutchison China). Mr. To founded Hutchison Whampoa Limited's TCM business. Mr. To has been Executive Chairman and Executive Director of Hutchison China MediTech Ltd. since 2006. He has been with Hutchison China for over twenty-six years, building its business from a small trading company to a billion dollar investment group. He joined Hutchison China in 1980. His career in China spans more than thirty years and he is well known to many of the top Government leaders in China. Mr. To has successfully put together deals with the world's leading industrial corporations such as Lockheed (US), Pirelli (Italy), Beiersdorf (Germany) as their China trade representative and consultant. Mr. To also created joint ventures with Procter & Gamble (P&G) to produce a wide range of consumer products in China, with China Southern Airlines and Lockheed, to do aircraft maintenance and engineering out of Guangzhou, China and with China National Aviation Corporation, British Airways and United Airlines to do aircraft maintenance at the new Hong Kong CLK airport. He serves as the Chairman of Hutchison MediPharma Limited. He serves as Director of Hutchison Whampoa (China) Limited and Hutchison BYS (Guangzhou) Holding Limited. He served as an Independent Non-Executive Director of China Southern Airlines Company Limited from June 1999 to December 16, 2005. He has been an Executive Director of Hutchison China MediTech Ltd. since 2000. Mr. To received a First Class Honours Bachelor's Degree in Mechanical Engineering from Imperial College of Science and Technology, London and an MBA from Stanford University's Graduate School of Business.

Mr. Johnny Cheng, BEc, CA has been Chief Financial Officer of Hutchison China MediTech Ltd. since July 2008. Mr. Cheng serves as Executive of Hutchison Whampoa Ltd. He has worked in Chi-Med as Chief Financial Officer for over two years. Prior to joining Chi-Med, Mr. Cheng was the Vice President, Finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008. Mr. Cheng started his career as an auditor with Price Waterhouse in Australia and then KPMG in Beijing before spending eight years with Nestle China where he was in charge of a number of finance and control functions in various operations. He has been an Executive Director at Hutchison China MediTech Ltd. since 2011. He serves as a Director of Hutchison MediPharma (Hong Kong) Limited and Sen Medicine Company Limited and was a director of Hutchison Healthcare Limited during 2009. Mr. Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is a member of the Institute of Chartered Accountants in Australia.

Dr. Zhenping Wu, Ph.D., M.B.A., has been Senior Vice President of Pharmaceutical Sciences of Hutchison China MediTech Ltd since 2012. Dr. Wu served as Vice President of Pharmaceutical Sciences for Hutchison MediPharma Ltd. Dr. Wu joined Hutchison MediPharma in 2008 with 17 years of experience in drug discovery and development in the pharmaceutical and biotechnology industry. His past positions include Senior Director of Pharmaceutical Sciences at Phenomix Corporation, a California based drug discovery and development company, Director of Pharmaceutical Development at Pfizer Global Research & Development in San Diego, California (formerly Agouron Pharmaceuticals), and Senior Scientist at Roche Palo Alto site. Dr. Wu led many development project teams and advanced numerous drug candidates into different phases of clinical development and commercialization. The candidates include Sutent, a new blockbuster anti-cancer drug for Pfizer. He served as Chairman and President of the Board of Sino-American Biotechnology and Pharmaceutical Association. He received a Colleague Recognition Award from Pfizer in 2003 for his work on the Sutent project, a Dean's Scholar Award from the University of California at Irvine in the same year and a Leadership Award from Sino-American Biotechnology and Pharmaceutical Association in 2008. Dr. Wu was the recipient of an American Heart Association Fellowship in 1990. Dr. Wu received a Ph. D. degree from Hong Kong University and an MBA degree from the University of California at Irvine.

Ms. May Wang, Ph.D. serves as Senior Vice President of Business Development & Strategic Alliances at Hutchison MediPharma Limited and served as its Vice President of Translational Science & Strategic Alliances. fDr. Wang serves as Vice President of Clinical Research & Strategic Alliances at Hutchison China MediTech Ltd. Prior to joining Hutchison MediPharma in 2010, Dr. Wang served as a Senior Research Advisor and Director at Eli Lily and Company. She has over seventeen years of drug discovery and development experience and was recognized for her contribution to the discovery of several drug cndidates for the treatment of infectious diseases, cancer and inflammatory disorders, including the HCV protease inhibitor Telapravir, in Phase ||| trials. Dr. Wang published more than fifty peer-reviewed papers and was credited as a co-inventor of numerous patents. Dr. Wang obtained her Ph.D. from Purdue University, USA.

Dr. Weiguo Su, Ph.D., has been the Chief Scientific Officer and Executive Vice President of Hutchison China MediTech Limited since 2012 and its Executive Director since March 27, 2017. Dr. Su served as a Senior Vice President of Drug Discovery at Hutchison MediPharma Limited. He joined Hutchison MediPharma in 2005, prior to which he spent fifteen years in Pfizer's US R&D organisation. Dr. Su delivered several high quality new drug candidates during his time with Pfizer with his last role being a Director in the Medicinal Chemistry Department. He holds Ph.D. and Post-doctoral Fellowship in Chemistry from Harvard University under the guidance of Nobel Laureate Professor E. J. Corey and his Bachelor's degree in Chemistry from Fudan University in Shanghai, China.

Mr. Hua Ye has been Head of Clinical Development & Regulatory Affairs and Senior Vice President at Hutchison China MediTech Ltd since 2014. Mr. Ye is a senior clinical research physician. He has fifteen years' drug development and global new drug registration experience in the pharmaceutical industry and six years' experience in cancer epidemiology. He worked at Shanghai Cancer Institute for 4 years and then went to McGill University to study cancer epidemiology. He started his career in the clinical trial field in the pharmaceutical industry. He worked as a biostatistician in the first 6 years in the industry during which time, he was the trial statistician of the pivotal phase 3 trial which contributed to the regulatory approval for Humira in the US and EU. He joined Novartis in 2004 and started working as a Medical Director. He advanced his career with increasing responsibilities in clinical development, he led a number of Phase 2 to 3 registration trials in the osteoarthritis, osteoporosis, infectious diseases, oncology and hematology disease areas. As clinical lead, he made contributions to the regulatory approval and lifecycle management for Reclast/Aclasta, Prexige, Zometa, Femara, Proleukin and Cardioxane in the US and EU. At Celgene, Ye led several clinical teams for Revlimid and Pomalyst global development in multiple myeloma and successfully obtained regulatory approval for Revlimid in multiple myeloma indication in China. He graduated from Fudan University Shanghai medical college in 1992 and graduated from McGill in 1999.